Sunitinib Capsules

Approved Indications & Uses of Sunitinib Capsules

Sunitinib is clinically approved for three primary oncological indications:

• Gastrointestinal Stromal Tumor (GIST): Treatment of gastrointestinal stromal tumors after disease progression on or intolerance to imatinib mesylate.
• Advanced Renal Cell Carcinoma (RCC): Approved as first-line targeted therapy and adjuvant therapy in patients at high risk of recurrent RCC following nephrectomy.
• Pancreatic Neuroendocrine Tumors (pNET): Treatment of progressive, well-differentiated, unresectable locally advanced or metastatic pancreatic neuroendocrine tumors.

Mechanism of Action (How Sunitinib Works)

Sunitinib exerts comprehensive multi-kinase inhibition:

• Multi-Targeted RTK Inhibition: Inhibits platelet-derived growth factor receptors (PDGFRα and PDGFRβ), vascular endothelial growth factor receptors (VEGFR1, VEGFR2, and VEGFR3), stem cell factor receptor (KIT), Fms-like tyrosine kinase-3 (FLT3), colony-stimulating factor-1 receptor (CSF-1R), and glial cell-line derived neurotrophic factor receptor (RET).
• Anti-Angiogenesis: By blocking VEGFR and PDGFR signaling, it halts the recruitment of endothelial cells and pericytes, starving tumors of oxygen and blood supply.
• Inhibition of Proliferation: Blocks downstream oncogenic signaling pathways, inhibiting tumor cell survival and triggering apoptosis.

Side Effects of Sunitinib

Common Side Effects:

• Fatigue, asthenia, and generalized weakness
• Gastrointestinal symptoms: Diarrhea, nausea, vomiting, stomatitis/mouth sores, and dyspepsia
• Palmar-plantar erythrodysesthesia (hand-foot syndrome) and skin rash
• Hypertension (elevated blood pressure)
• Yellow discoloration of skin and depigmentation/hair lightening
• Dysgeusia (metallic taste or loss of taste sensation)
• Decreased appetite and weight loss

Serious Adverse Events Requiring Urgent Intervention:

• Hepatotoxicity, hepatic failure, and elevated transaminases
• Cardiovascular dysfunction: Left ventricular ejection fraction (LVEF) reduction, congestive heart failure, and myocardial ischemia
• QTc interval prolongation and torsades de pointes
• Severe hemorrhagic events (gastrointestinal, respiratory, or intracranial hemorrhage)
• Osteonecrosis of the Jaw (ONJ)
• Gastrointestinal perforation and fistula formation
• Thrombotic Microangiopathy (TMA) including thrombotic thrombocytopenic purpura (TTP) and hemolytic uremic syndrome (HUS)

Clinical Precautions & Administration

• Administration: Sunitinib capsules are taken orally once daily with or without food. Capsules must be swallowed whole with water; never crush, chew, or open the capsules.
• Wound Healing: Withhold Sunitinib at least 3 weeks prior to elective surgery or dental surgery due to impaired angiogenesis and wound breakdown.
• Dental Exam: Perform an oral exam and resolve invasive dental issues prior to starting Sunitinib to prevent Osteonecrosis of the Jaw.
• Pre-Existing Conditions: Use with heightened vigilance in patients with heart failure, uncontrolled hypertension, diabetes (risk of hypoglycemia), bleeding disorders, or history of peptic ulcers.

Warnings & Contraindications

• Pregnancy: Contraindicated during pregnancy; causes severe fetal harm and embryofetal lethality. Strict barrier contraception must be used during therapy and for at least 4 weeks after the final dose.
• Lactation: Avoid breastfeeding during therapy and for 4 weeks post-treatment.
• Grapefruit: Avoid grapefruit and grapefruit juice, which inhibit CYP3A4 metabolism and dramatically increase sunitinib toxicity.
• Hypersensitivity: Absolutely contraindicated in patients with known hypersensitivity to sunitinib malate.

Drug Interactions

• Strong CYP3A4 Inhibitors: Ketoconazole, itraconazole, clarithromycin, and ritonavir elevate sunitinib concentrations; dose adjustments may be warranted.
• Strong CYP3A4 Inducers: Rifampin, carbamazepine, phenytoin, dexamethasone, and St. John's Wort markedly reduce sunitinib levels and therapeutic efficacy.
• QT-Prolonging Medications: Antiarrhythmics, antipsychotics, fluoroquinolones (levofloxacin), and fluconazole heighten cardiac arrhythmia risks.
• Anticoagulants & Blood Thinners: Concomitant use with warfarin, low-molecular-weight heparins, or NSAIDs elevates hemorrhagic complications.

Important Monitoring Parameters

• Blood pressure: Monitor at baseline and frequently during treatment cycles.
• Cardiac function: Baseline and periodic LVEF assessment via echocardiography or MUGA scan.
• Thyroid function tests: Baseline and regular TSH monitoring (hypothyroidism occurs frequently).
• Complete blood counts (CBC): Monitor for severe neutropenia, lymphopenia, and thrombocytopenia.
• Blood glucose: Regular monitoring, particularly in diabetic patients, due to potential hypoglycemia.
• Liver and renal function panels: Regular ALT, AST, bilirubin, creatinine, and urinalysis (proteinuria).

Storage Information

Store Sunitinib capsules at controlled room temperature (20°C to 25°C / 68°F to 77°F) in a dry environment away from moisture and direct sunlight. Keep out of reach of children.